WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-10 10:25 am Purchase | 2024-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | WELLINGTON MANAGEMENT GROUP LLP | 5,307,326 8.200% | 688,967 (+14.92%) | Filing |
| 2024-11-08 10:52 am Sale | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | WELLINGTON MANAGEMENT GROUP LLP | 4,618,359 7.170% | -197,199 (-4.10%) | Filing |
| 2024-02-08 10:21 am Purchase | 2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR | WELLINGTON MANAGEMENT GROUP LLP | 4,815,558 8.680% | 224,469 (+4.89%) | Filing |
| 2023-02-06 3:02 pm Purchase | 2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR | WELLINGTON MANAGEMENT GROUP LLP | 4,591,089 8.370% | 1,896,275 (+70.37%) | Filing |
| 2022-02-04 09:27 am Purchase | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | WELLINGTON MANAGEMENT GROUP LLP | 2,694,814 5.240% | 2,694,814 (New Position) | Filing |